Bradykinin B₂ Receptor Gene C-58T Polymorphism and Insulin Resistance. A Study on Obese Patients

Abstract

The bradykinin B₂ receptor (B₂R) gene is a candidate in the pathogenesis of insulin resistance, which often clusters with other abnormalities in metabolic syndrome. We investigated the distribution of the C-58T B₂R gene polymorphism within a population of overweight/obese patients (BMI ≥ 25 kg/m²) potentially characterised by different levels of insulin resistance. Patients with type 2 diabetes, dyslipidemia and hypertension were excluded in order to distinguish the effect of obesity on insulin sensitivity from that of confounding factors. Ninety-two unrelated adults (41 men and 51 women, aged 33.7 ± 11.6 years) were recruited by random sampling from a general population evaluated for cardiovascular risk stratification. Measurements included BMI, waist circumference, body composition, blood pressure, serum leptin, and lipid profile. Insulin sensitivity was calculated according to the homeostasis model assessment (HOMA) method. C-58T genotypes - CC (n = 20), CT (n = 47) and TT (n = 25) - were determined by restriction fragment-length polymorphism PCR. Patients subdivided on the basis of C-58T polymorphism, showed no difference in any of the parameters examined, including HOMA index values, after adjustment for age, sex, BMI and waist circumference. The results indicate that the C-58T B₂R gene polymorphism is not associated with different levels of insulin resistance within a population of obese patients.

Bradykinin receptor - Gene polymorphism - Obesity

References

• 1 Isami S, Kishikawa H, Araki E, Uehara M, Kaneko K, Shirotani T, Todaka T, Ura S, Motoyoshi S, Matsumoto K, Miyamura N, Shichiri M. Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway.  Diabetologia. 1996;  39 412-420
• 2 Figueroa C D, Dietze G, Muller-Esterl W. Immunolocalization of bradykinin B2 receptors on skeletal muscle cells.  Diabetes. 1996;  45 (suppl 1) S24-S28
• 3 Motoshima H, Araki E, Nishiyama T, Taguchi T, Kaneko T, Hirashima Y, Yoshizato K, Shirakami A, Sakai K, Kawashima J, Shirotani T, Kishikawa H, Shichiri M. Bradykinin enhances insulin receptor tyrosine kinase in 32D cells reconstituted with bradykinin and insulin signalling pathways.  Diabetes Res Clin Pract. 2000;  48 55-170
• 4 Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity.  Hypertension. 2001;  38 1355-1360
• 5 Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y, Korumatani H, Kobayashi F, Kanmatsuse K, Kajiwara N. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.  Hypertension. 1994;  23 450-455
• 6 Morel Y, Gadient A, Keller U, Vadas L, Galay A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol.  J Cardiovasc Pharmacol. 1995;  26 306-311
• 7 Braun A, Kammerer S, Maier E, Bohme E, Roscher A A. Polymorphisms in the gene for the human B2-bradykinin receptor: new tools assessing a genetic risk for bradykinin-associated diseases.  Immunopharmacology. 1996;  33 32-35
• 8 Reaven G M. Banting Lecture 1988: role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
• 9 DeFronzo R A, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.  Diabetes Care. 1991;  114 173-194
• 10 National Institutes of Health. National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report.  Obes Res. 1998;  6 (Suppl. 2) S51-S210
• 11 Heitmann B L. Prediction of body water and fat adult Danes from measurement of electrical impedance. A validation study.  Int J Obes. 1990;  14 789-902
• 12  . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 1998;  21 (suppl 1) S5-S19
• 13  . 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension.  J Hypertens. 1999;  17 151-183
• 14 Vettor R, De Pergola G, Pagano C, Englaro P, Laudadio E, Giorgino F, Blum W, Giorgino R, Federspil G. Gender differences in serum leptin in obese people: relationship with testosterone, body fat distribution, and insulin sensitivity.  Eur J Clin Invest. 1997;  27 1016-1024
• 15 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentration in man.  Diabetologia. 1985;  28 412-419
• 16 Bonora E, Targher G, Alberiche M, Bonadonna R C, Saggiani F, Zenere M B, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity.  Diabetes Care. 2000;  23 57-63
• 17 Sartori M T, Vettor R, De Pergola G, De Mitrio V, Maggiorato G, Della Mea P, Patrassi G M, Lombardi A M, Fabris R, Girolami A. Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients.  Thromb Haemost. 2001;  86 1161-1169
• 18 Mulatero P, Williams T A, Milan A, Paglieri C, Rabbia F, Fallo F, Veglio F. Blood pressure in patients with primary aldosteronism is influenced by bradykinin B₂ receptor and α-adducin gene polymorphism.  J Clin Endocrinol Metab. 2002;  87 3337-3343
• 19 Gainer J V, Brown N J, Bachvarova M, Bastien L, Maltais I, Marceau F, Bachvarov D R. Altered frequency of a promoter polymorphism in the kinin B₂-receptor gene in hypertensive African-Americans.  Am J Hypertens. 2000;  13 1268-1273
• 20 Tai E S, Emmanuel S C, Chew S K, Tan B Y, Tan C E. Isolated low HDL cholesterol: an insulin resistant state only in the presence of fasting hypertriglyceridemia.  Diabetes. 1999;  48 1088-1092
• 21 Szanto I, Kahan R. Selective interaction between leptin and insulin signalling pathways in hepatic cell line.  Proc Natl Acad Sci USA. 2000;  97 2355-2360
• 22 Regoli D, Barabe J. Pharmacology of bradykinin and related kinins.  Pharmacol Rev. 1980;  32 1-46
• 23 Tsukahara Y, Itakura A, Ohno Y, Ando H, Mizutani S. Umbilical plasma kininase I activity in fetal hypoxya.  Horm Metab Res. 2003;  13 1268-1273
• 24 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico M A, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance and hypertension.  N Engl J Med. 1987;  317 350-356